Siemens Healthineers is making aggressive moves into new medical frontiers even as significant financial pressures mount. The medtech giant is pushing deeper into neurology diagnostics and radiopharmaceuticals, areas traditionally dominated by large pharmaceutical companies, while simultaneously grappling with a perfect storm of tariffs, currency effects, and a slowdown in China.
The company’s strategic pivot is clear. It has joined the Global Alzheimer’s Platform Foundation’s large-scale Bio-Hermes-002 study, working alongside industry leaders like Biogen, Eli Lilly, and Roche to develop blood-based and digital biomarkers for the early detection of amyloid and tau deposits in the brain. Concurrently, it is expanding its radiopharmacy portfolio through a new supply agreement with Radiopharm Theranostics. This deal secures manufacturing for the imaging agent RAD101, which has FDA Fast-Track status for a U.S. Phase 3 trial aimed at more precisely identifying brain metastases—a market with an addressable patient potential exceeding 300,000 cases annually in the United States alone.
To orchestrate this technological leap, CEO Bernd Montag is reshaping the leadership team. Martin Stumpe, formerly of Google and Danaher, will take over as Chief Technology Officer on June 1, 2026. His mandate is to significantly expand the company’s AI capabilities, with a particular focus on “Patient Twinning” technology for advanced diagnostics. Stumpe is scheduled to present his program for the first time at the DMEA trade fair in Berlin starting April 21.
These ambitious growth initiatives, however, are colliding with a harsh operational reality. The company faces a tariff impact of approximately 400 million euros and negative currency effects of 200 to 250 million euros, which are eroding profitability. Management has already revised its full-year guidance for adjusted earnings per share (EPS) downward to a range of 2.20 to 2.40 euros, compared to 2.39 euros in the prior year. This correction follows a first quarter where revenue grew 3.8% but adjusted EPS fell 3% to 0.49 euros.
Should investors sell immediately? Or is it worth buying Siemens Healthineers?
A primary area of weakness is the Diagnostics division, which recently shrank by three percent. China’s strict anti-corruption campaign in healthcare has centralized procurement processes, severely dampening local revenues. The stock price reflects these burdens, currently trading at 38.40 euros. This marks a year-to-date decline of roughly 14 percent and places the shares about 23 percent below their 52-week high of 49.86 euros. The significant gap to the 200-day moving average at 44.19 euros underscores the persistent downward trend.
Adding another layer of uncertainty for investors is the pending spin-off of Siemens AG’s 30 percent stake in Healthineers. Siemens AG had promised to communicate details on the distribution “at the beginning of the second calendar quarter of 2026,” a deadline that has now passed without a concrete announcement. Post-spin-off, Healthineers would need to independently refinance liabilities of up to 13.9 billion euros. Goldman Sachs has already cut its price target from 52 to 45 euros, citing the stake reduction by Siemens AG as a burden, while maintaining a “Neutral” rating.
All eyes are now on the company’s second-quarter results, due on May 7. Analysts anticipate mid- to high-single-digit growth in the Imaging and Precision Therapy segments. Such a performance is considered essential to offset the ongoing softness in Diagnostics. Should management also choose that day to finally provide concrete details on the planned spin-off, it could deliver the crucial catalyst needed for a potential technical rebound. Until then, the company’s bold strategic flight forward continues against a stiff financial headwind.
Ad
Siemens Healthineers Stock: Buy or Sell?! New Siemens Healthineers Analysis from April 16 delivers the answer:
The latest Siemens Healthineers figures speak for themselves: Urgent action needed for Siemens Healthineers investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 16.
Siemens Healthineers: Buy or sell? Read more here...
